0001193125-23-197705.txt : 20230728 0001193125-23-197705.hdr.sgml : 20230728 20230728160904 ACCESSION NUMBER: 0001193125-23-197705 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230724 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230728 DATE AS OF CHANGE: 20230728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERU INC. CENTRAL INDEX KEY: 0000863894 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 391144397 STATE OF INCORPORATION: WI FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13602 FILM NUMBER: 231123096 BUSINESS ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 BUSINESS PHONE: 3125959123 MAIL ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: FEMALE HEALTH CO DATE OF NAME CHANGE: 19960205 FORMER COMPANY: FORMER CONFORMED NAME: WISCONSIN PHARMACAL COMPANY INC DATE OF NAME CHANGE: 19920703 8-K 1 d515262d8k.htm 8-K 8-K
false 0000863894 --09-30 0000863894 2023-07-24 2023-07-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2023

 

 

VERU INC.

(Exact name of registrant as specified in its charter)

 

 

 

Wisconsin   1-13602   39-1144397

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127

Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   VERU   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Section 5 – Corporate Governance and Management

 

Item 5.03.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On July 24, 2023, Veru Inc. (the “Company”) filed the Articles of Amendment with the Wisconsin Department of Financial Institutions. The Articles of Amendment increase the total number of authorized shares of the Company’s common stock from 154,000,000 to 308,000,000. The Articles of Amendment are attached as Exhibit 3.1 to this report and are incorporated herein by reference.

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

A special meeting of the shareholders of the Company (the “Special Meeting”) was held on July 24, 2023. A total of 89,236,732 shares of the Company’s common stock were eligible to vote at the Special Meeting. The matters voted on at the Special Meeting were as follows:

 

1.

Share Increase Proposal:

The shareholders voted to approve an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock of the Company from 154,000,000 to 308,000,000.

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

62,042,114   3,935,354   199,316   0

 

2.

Adjournment Proposal:

The shareholders voted in favor of approving the adjournment of the Special Meeting.

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

61,372,471   4,391,943   412,370   0

Section 9 – Financial Statements and Exhibits

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed herewith:

 

Exhibit
No.

  

Description

 3.1    Articles of Amendment to Amended and Restated Articles of Incorporation of Veru Inc.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 28, 2023     VERU INC.
    By:  

/s/ Michele Greco

      Michele Greco
      Chief Financial Officer and
Chief Administrative Officer

 

3

EX-3.1 2 d515262dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

ARTICLES OF AMENDMENT TO THE

AMENDED AND RESTATED ARTICLES OF INCORPORATION OF

VERU INC.

1. The name of the Corporation is Veru Inc.

2. The amendment adopted relates to Article V of the Amended and Restated Articles of Incorporation. The first portion of Article V is amended to read as follows:

ARTICLE V

The aggregate number of shares which the Corporation shall have the authority to issue is 313,015,000 shares consisting of:

(a) 308,000,000 shares designated as “Common Stock” with a par value of $0.01 per share;

(b) 5,000,000 shares designated as “Class A Preferred Stock” with a par value of $0.01 per share; and

(c) 15,000 shares designated as “Class B Preferred Stock” with a par value of $0.50 per share and the relative rights, preferences and privileges of each class shall be as follows:

The remainder of Article V, as previously amended, remains unchanged.

3. The foregoing amendment to the Amended and Restated Articles of Incorporation of the Corporation, was approved and adopted by the Board of Directors of the Corporation on May 9, 2023 and the shareholders of the Corporation on July 24, 2023 in accordance with Section 180.1003 of the Wisconsin Business Corporation Law.


Dated this 24th day of July, 2023.

 

VERU INC.
BY   /s/ Mitchell S. Steiner
  Mitchell S. Steiner, Chairman, President and Chief Executive Officer

This document was drafted by Christopher M. Hruska, Esq.

Please return this document to:

Tanya R. Braga, Paralegal

Reinhart Boerner Van Deuren s.c.

1000 North Water Street, Suite 1700

Milwaukee, WI 53202

(414) 298-8354

tbraga@reinhartlaw.com

 

2

EX-101.SCH 3 veru-20230724.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 veru-20230724_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 veru-20230724_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jul. 24, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000863894
Current Fiscal Year End Date --09-30
Document Type 8-K
Document Period End Date Jul. 24, 2023
Entity Registrant Name VERU INC.
Entity Incorporation State Country Code WI
Entity File Number 1-13602
Entity Tax Identification Number 39-1144397
Entity Address, Address Line One 2916 N. Miami Avenue
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33127
City Area Code (305)
Local Phone Number 509-6897
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol VERU
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d515262d8k_htm.xml IDEA: XBRL DOCUMENT 0000863894 2023-07-24 2023-07-24 false 0000863894 --09-30 8-K 2023-07-24 VERU INC. WI 1-13602 39-1144397 2916 N. Miami Avenue Suite 1000 Miami FL 33127 (305) 509-6897 false false false false Common Stock, $0.01 par value per share VERU NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d515262d8k.htm d515262dex31.htm veru-20230724.xsd veru-20230724_lab.xml veru-20230724_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d515262d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d515262d8k.htm" ] }, "labelLink": { "local": [ "veru-20230724_lab.xml" ] }, "presentationLink": { "local": [ "veru-20230724_pre.xml" ] }, "schema": { "local": [ "veru-20230724.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "veru", "nsuri": "http://verupharma.com/20230724", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d515262d8k.htm", "contextRef": "duration_2023-07-24_to_2023-07-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d515262d8k.htm", "contextRef": "duration_2023-07-24_to_2023-07-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://verupharma.com//20230724/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-197705-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-197705-xbrl.zip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end